Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
  • A01N33/02—Amines; Quaternary ammonium compounds
  • A01N33/12—Quaternary ammonium compounds
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
  • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
  • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
  • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
  • A01N47/44—Guanidine; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
  • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/02—Local antiseptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• Patent Document 5 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide and found that this compound is also specifically effective against norovirus.
• Patent Document 5 the norovirus inactivating agent of Patent Document 5 is excellent, there is still room for study to improve its performance in terms of its rapid effect on virus inactivation.
• the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or different, and the direct number of carbon atoms is 8 to 20. (Representing a chain saturated hydrocarbon), trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different and represent a linear saturated hydrocarbon having 1 to 18 carbon atoms), 1.
• the present invention is characterized in that (c) ethanol is blended in an amount of 10% by mass to 80% by mass in the virus inactivating agent composition having the above constitution.
• the present invention is characterized in that, in the virus inactivating agent composition having the above constitution, the blending amount of (c) ethanol is 35% by mass to 65% by mass.
• the compounding mass ratio (a) / (b) of the (b) virus inactivating efficacy enhancing component to the (a) virus inactivating component is determined. , 0.001 ⁇ (a) / (b) ⁇ 250.
• the present invention comprises (a) a virus inactivating agent composition containing 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water as a virus inactivating component.
• a virus inactivating efficacy enhancing component one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid. It is a method for enhancing virus inactivating efficacy, which is characterized by addition.
• the present invention is also a method for inactivating a non-enveloped virus in which the virus inactivating agent composition having the above constitution is brought into contact with the non-enveloped virus.
• a cationic virus inactivating component of 0.01% by mass to 5.0% by mass as a virus inactivating component, and (b) a virus inactivating effect.
• a virus inactivating agent composition is excellent in usability without fear of irritation due to alkali to the skin and has excellent rapid effect in virus inactivation.
• the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or the same or Unlike each other, it represents a linear saturated hydrocarbon having 8 to 20 carbon atoms) and a trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different from each other and have 1 to 18 carbon atoms.
• virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
• the cationic virus inactivating component is 1,4-bis (3,3'-(1). -Decilpyridinium) Methyloxy) Butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate, and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride.
• a virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
• the amount of (c) ethanol blended is 35% by mass to 65% by mass, so that the virus A virus with excellent quick-drying properties can be more effectively improved in inactivation, less likely to cause skin irritation during use, and effectively improve the volatilization of the virus inactivating agent composition. It becomes an inactivating agent composition.
• the virus inactivating agent composition having the configuration of any one of the first to fifth above, (a) the virus is inactive against the virus inactivating component (b).
• the compounding mass ratio (a) / (b) of the compounding efficacy enhancing component is 0.001 ⁇ (a) / (b) ⁇ 250, the rapid effect in virus inactivation can be further improved.
• the virus inactivating component contains 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water.
• the virus inactivating agent composition is selected from the group consisting of (b) 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid as a virus inactivating efficacy enhancing component.
• the (a) cationic virus inactivating component compounded as a virus inactivating component in the virus inactivating agent composition of the present invention has a high virus inactivating effect, but is virus inactivating. There was room for consideration in the rapid effect on activation.
• a cationic virus inactivating component in combination with one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, in virus inactivation. It is the first finding by the present inventors that the rapid effect could be improved synergistically.
• an organic acid and / or an inorganic acid which is a virus inactivating efficacy enhancing component is a virus inactivating agent. It is blended in an amount of 0.02% by mass or more and 10.0% by mass or less with respect to the composition, preferably 0.03% by mass or more and 5.0% by mass or less, and 0.10% by mass or more and 2.0% by mass or less. The following is more preferable.
• any of anionic surfactant, nonionic surfactant and amphoteric surfactant is preferably used.
• the blending amount of the surfactant in the virus inactivating agent composition of the present invention is not particularly limited, but is preferably 0.1% by mass or more and 10% by mass or less.
• the cationic virus inactivating component contained in the virus inactivating agent composition of the present invention is not included in the surfactant in the present specification.
• anionic surfactants include fatty acid soaps, alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, ⁇ -olefin sulfonates, alkyl phosphate ester salts, polyoxyethylene alkyl ether sulfates, etc. Examples thereof include polyoxyethylene alkyl phenyl ether sulfate and polyoxyethylene alkyl ether phosphate.
• nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerin fatty acid esters, and polyoxyethylene hydrogenated castor oil. , Palm oil fatty acid diethanolamide, polyoxyethylene polyoxypropylene alkyl ether, fatty acid alkanolamide, alkylamine oxide and the like.
• amphoteric surfactants include betaine-type surfactants. Specific examples thereof include lauryl-N, N-dimethylacetate betaine, laurylamide propyl-N, N-dimethylacetate betaine, coconut alkylamide propyl-N, N-dimethylhydroxypropyl sulfobetaine and the like.
• the virus inactivating agent composition of the present invention is an aqueous type, and water is mainly used as the solvent.
• water examples include purified water such as ion-exchanged water and reverse osmosis membrane water, ordinary tap water, industrial water, and deep ocean water.
• virus inactivating agent composition of the present invention as other components, as necessary, antibacterial agents other than cationic virus inactivating components, virus inactivating agents, algae-proofing agents, rust-preventing agents, etc.
• a solvent, a chelating agent, a fragrance, a deodorant component, a pH adjuster, a moisturizing component, a thickener, etc. within a range that does not impair the effects of the present invention, an antibacterial effect, a virus inactivating effect, an algae-proofing effect, etc.
• Anti-corrosion effect, cleaning effect, fragrance, deodorant property, moisturizing effect, thickening effect and the like may be imparted.
• the solvent examples include normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, vaseline, squalane, hydrocarbon solvent such as ⁇ -olefin oligomer, 1-propanol, 2-propanol (IPA), 1-butanol, 2 -Alcohol solvents such as butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol, 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-
• glycol-based solvents such as 2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether.
• fragrances include limonene such as d-lymonen, pinen such as ⁇ -pinen and ⁇ -pinen, simen such as p-simene, hydrocarbon fragrances such as inden and cariophyllene, linalol, geraniol, citronellol, and l-menthol.
• Vanillin, Ethylvanylin and other phenolic fragrances octanal, nonanal, undecylaldehyde, undecanal, decylaldehyde, n-butylaldehyde, isobutylaldehyde, hexylaldehyde, citral, terpineol, benzaldehyde, cinnamic aldehyde, anisaldehyde, cumin Aldehyde-based fragrances such as aldehydes, adxal, amilcinnamic aldehydes, and cyclamen aldehydes, muskketones, carboxylics, mentons, cerebral brains, camphor, acetophenone, butyrophenone, tonalide, ⁇ -ionone, ⁇ -ionone, ⁇ -methylionone, ⁇ -methylionone, ⁇ -Ketone-
• deodorant components include sugar cane extract, green tea extract, cha dry distillate, persimmon extract, grapefruit extract, mozochiku extract, yuzu seed extract, and lotus extract, but in addition to the deodorizing effect. Therefore, sugar cane extract is suitable from the viewpoint of promoting the inactivating action of norovirus.
• pH adjuster examples include other organic acids such as acetic acid, malic acid and salicylic acid, other inorganic acids such as hydrochloric acid, sodium citrate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide and the like.
• moisturizing ingredients include glycols such as glycerin, propylene glycol and 1,3-butylene glycol, and polyhydric alcohols such as sorbitol.
• thickeners examples include carboxyvinyl polymers, which are cross-linked polyacrylic acids, cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and hydroxypupyl cellulose, xanthan gum, guar gum, arabic gum, sodium alginate, propylene glycol alginate, and ethyl cellulose. , Sodium polyacrylate, cyclodextrin and the like.
• the virus inactivating agent composition of the present invention thus obtained is applied or sprayed to a place touched by a virus-infected person, a place where a virus-infected person's vomit is treated, or a place contaminated with a virus such as clothes. Therefore, the virus can be effectively removed.
• the virus adhering to the fingers or the like can be effectively removed and the fingers or the like can be disinfected.
• the virus inactivating composition of the present invention is highly resistant to enveloped viruses such as influenza virus, coronavirus and herpesvirus, as well as non-enveloped viruses such as norovirus, rotavirus, rhinovirus and adenovirus. Has an activating effect. Therefore, it can also be suitably used for inactivating norovirus, which was difficult to inactivate with conventional virus removing agents.
• test virus solution 0.1 mL was added and mixed with 0.9 mL of the test solutions of the present inventions 1 to 10 and Comparative Examples 1 to 6 prepared in Example 1 to prepare an action solution. After 1 minute, the working solution was diluted 100-fold with MEM medium to prepare a 10-fold dilution series. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.
• Comparative Examples 5 and 6 containing only the component (a) and Comparative Examples 1 to 3 containing only the component (b) were against feline calicivirus. Therefore, the reduction value of the infectious titer log was smaller than 1.5, and a sufficient virus inactivating effect was not observed. Further, in Comparative Example 4 in which the component (a) was replaced with the cationic virus inactivating component and isopropylmethylphenol, which is another virus inactivating component, was used, the component (b) was used in combination for immediate effect. No virus inactivating effect was obtained, and no enhancing effect was observed in the component (b).
• the infectious titer logarithmic reduction value was 3.0. It was confirmed that a faster-acting virus inactivating effect could be obtained.
• test virus solution 0.1 mL was added and mixed with 0.9 mL of the test solution of the present invention 12 prepared in Example 1 to prepare an action solution. After 3 minutes, the working solution was diluted 100-fold with MEM medium to stop the action, and the virus infectious titer was measured as the stock solution of the sample for infectious titer measurement. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Plant Pathology (AREA)
• Pest Control & Pesticides (AREA)
• Environmental Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dentistry (AREA)
• Agronomy & Crop Science (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Virology (AREA)
• Toxicology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Medicinal Preparation (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=80350349

Family Applications (1)

Country Status (3)

Cited By (2)

Citations (7)

Family Cites Families (6)

• 2021
  • 2021-07-21 JP JP2022543335A patent/JPWO2022038955A1/ja active Pending
  • 2021-07-21 WO PCT/JP2021/027348 patent/WO2022038955A1/ja active Application Filing
  • 2021-07-21 CN CN202180058669.4A patent/CN116056570B/zh active Active

Patent Citations (7)

Also Published As

Similar Documents

Legal Events